CATALYSTYahoo Finance • 7h ago
Veraxa Biotech stock gains on FDA-aligned testing strategyYahoo Finance report covering Veraxa Biotech AG (VRXA) market action, institutional positioning, and fundamental catalysts.
Why VRXA Stock advanced +0.89% Today — RQD Quant Desk Flash
$1.14 +0.89% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.14
Veraxa Biotech AG (VRXA) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C- • HOLD / WATCH
Cap $159.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on VRXA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is VRXA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Veraxa Biotech AG (NASDAQ: VRXA) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $1.14 (+0.89% 1D, market cap $159.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, VRXA ranks #177 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does VRXA compare to PDSB and CNTN in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRXA carries a Roarable C- (60/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PDSB (PDS Biotechnology Corporation) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $162.8M) and CNTN (Canton Strategic Holdings Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -4.1%, cap $163.3M). Among the 5-stock peer group, VRXA leads on earnings multiple (N/A) while CNTN leads on capital efficiency (-4.1% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for VRXA?
▼
For Veraxa Biotech AG (VRXA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #177 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.14 (-0.03%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 60/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.4% avg 90D alpha vs SPY • 53.5% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C-
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE+0.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VRXA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (60/100 Composite)
🔍 WHY VRXA SCORES 60/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (22% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B-$1.26-11.9% Next Q
68
Q2 (-2Q)Grade C+$1.11-9.9% Next Q
65
Q3 (-1Q)Grade C+$1.00+14% Next Q
63
CurrentGrade C-$1.14+0.4% Hist 90D α
60
Trajectory: B- (68) → C- (60)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the VRXA Bull Thesis Could Fail
Even with a 60/100 (C-) score, VRXA faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($1.33) or 200D SMA ($6.97) invalidates the momentum regime and cuts Target Base ($1.15) toward Bear Floor ($0.90).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $VRXA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VRXA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why VRXA Stock advanced +0.89% Today — RQD Quant Desk Flash
Veraxa Biotech AG (VRXA) advanced +0.89% to $1.14, trading at 2% of its 52-week range ($0.95 – $27.36). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.95 – $27.36) with RSI-14 at 47.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.14 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C- (Hold) backed by 52% gross margin and $4.5M annual free cash flow.
Live VRXA Headlines & Catalysts
MARKET WIRETradingView • 10h ago
VERAXA Biotech AG (VRXA) Reports First In Vivo Proof-of-Concept for BiTAC-ADCTradingView report covering Veraxa Biotech AG (VRXA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 13h ago
A director buys Veraxa Biotech (VRXA) shares at $0.98 and $1.Stock Titan report covering Veraxa Biotech AG (VRXA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 16h ago
VERAXA Biotech (VRXA) Advances FDA-Aligned Methods to Reduce Animal TestingYahoo Finance report covering Veraxa Biotech AG (VRXA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com Nigeria • 19h ago
Form 4 Veraxa Biotech AG - Post de-SPAC: Marc Gruninger (Director) For: 27 OctoberInvesting.com Nigeria report covering Veraxa Biotech AG (VRXA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 22h ago
VERAXA Biotech (VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC CongressYahoo Finance report covering Veraxa Biotech AG (VRXA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 1d ago
Veraxa Biotech AG Stock Price Prediction: Today, Tomorrow, Next Week (VRXA)Traders Union report covering Veraxa Biotech AG (VRXA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETraders Union • 1d ago
Veraxa Biotech AG Stock Price Today | VRXA Live Chart & NewsTraders Union report covering Veraxa Biotech AG (VRXA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 12d ago
VERAXA Biotech (VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer PipelineVERAXA is implementing FDA-aligned New Approach Methodologies ("NAMs") across its preclinical research programs, aiming to improve the relevance of experimental findings to human biology while reducing animal testing. Th
MARKET WIREYahoo • 20d ago
VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC CongressIn vivo data confirm activation of prodrug payload inside tumor cells following systemic administration of BiTAC-ADC molecules leading to potent anti-tumor activityZURICH, SWITZERLAND – October 13, 2026 -- VERAXA Biotech
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (VRXA Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
VRXA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -91.09%⚡ TESTING RESISTANCE
2026-10-30O $1.15H $1.25L $1.08C $1.14VOL 261.4K
RES: $1.15SUP: $0.89SMA50: $1.33SMA200: $6.97
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
VRXA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on VRXA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for VRXA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VRXA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VRXA)
Health Care Rank #177 of 1016
⚔️ PDSB vs VRXA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (VRXA vs. PDSB, CNTN, CUE, NGEN)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Veraxa Biotech AG (VRXA) ranks #177 by composite RQD confidence (60/100, grade C-) and #603 by equity capitalization ($159.8M). Within this direct 5-issuer industry benchmark cohort, VRXA leads on earnings valuation at N/A trailing P/E, while CNTN leads on capital efficiency and profitability with -4.1% ROIC and — gross margin. VRXA currently leads its immediate peer cohort in composite quantitative strength at 60/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VRXA
ACTIVE
Veraxa Biotech AG | C- | 60/100 | — | — | — | +0.89% | $159.8M | Benchmark Subject |
| PDSB PDS Biotechnology Corporation | D | 45/100 | — | — | -35.0% | -7.10% | $162.8M | /pdsb-vs-vrxa → |
| CNTN Canton Strategic Holdings Inc. | D- | 37/100 | — | — | -4.1% | -4.88% | $163.3M | /cntn-vs-vrxa → |
| CUE Cue Biopharma Inc. | E | 33/100 | — | — | -35.0% | -2.70% | $155.8M | /cue-vs-vrxa → |
| NGEN NervGen Pharma Corp. | D | 49/100 | — | — | — | -4.86% | $155.0M | /ngen-vs-vrxa → |
2. VRXA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTVeraxa Biotech AG (VRXA) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $159.8M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. VRXA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs VRXA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Veraxa Biotech AG (NASDAQ: VRXA) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $1.14 (+0.89% 1D, market cap $159.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, VRXA ranks #177 in composite RQD confidence.
How does VRXA compare to PDSB and CNTN in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRXA carries a Roarable C- (60/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PDSB (PDS Biotechnology Corporation) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $162.8M) and CNTN (Canton Strategic Holdings Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -4.1%, cap $163.3M). Among the 5-stock peer group, VRXA leads on earnings multiple (N/A) while CNTN leads on capital efficiency (-4.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for VRXA?
For Veraxa Biotech AG (VRXA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #177 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where is VRXA trading relative to its 50-day, 200-day, and 52-week technical levels?
VRXA last traded at $1.14 (+0.89% on volume of 261,438 shares), positioning the stock -14.29% below its 50-day simple moving average ($1.33) and -83.64% below its 200-day simple moving average ($6.97). Across its 52-week range of $0.95 to $27.36, VRXA sits at the 0.7% percentile with a 14-day RSI of 47.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.28).
VRXA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is VRXA stock moving today?
Why VRXA Stock advanced +0.89% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
ROARABLE RATING BRIEF • RQD 60/100 (C-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
VRXA — Veraxa Biotech AG: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:17:48Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, VRXA scores 60 out of 100, a letter grade of C-, with a verdict label of "Roarable Hold — Cautious Neutral." The Fundamental Cash Engine pillar scores 12 of 20, reflecting an ROIC of 0% and an FCF yield of 0%; for a prospective investor, this means the rating system sees no current return on invested capital and no free-cash yield to support the share price. The Whale/13F Flow pillar scores 13 of 20 on institutional accumulation and options positioning, indicating some modest institutional support, though the underlying holder detail is not itemized in the source data. The Insider Conviction pillar scores 9 of 20 on SEC Form 4 and Congressional PTR cluster flow, the lowest pillar in the set, which signals weaker insider-driven confidence signals. The Macro Regime Fit pillar scores 13 of 20 with a beta of 1.0 and a sector sensitivity assessment, suggesting market-level volatility exposure roughly in line with the broad market. The Forensic Balance Sheet pillar scores 13 of 20 using an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5, which is the strongest relative pillar and points to a balance sheet that is neither distressed nor strong. Taken together, the upside case rests on institutional interest, a moderate balance sheet, and recent clinical-stage news flow, while the valuation tradeoff is that the company currently shows no reported profitability, no free cash generation, and a share price that has traded between $0.95 and $27.36 over the past 52 weeks, so the rating reflects caution rather than conviction.
Business
Veraxa Biotech AG (VRXA) is a NASDAQ-listed issuer classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company is publicly traded with a market capitalization of $0.2B. The source data does not describe its products, customers, or revenue model in detail. Recent news references a BiTAC-ADC platform and FDA-aligned testing methods, which are described in the catalysts section below.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. For a prospective investor, the absence of mapped links means ripple effects from suppliers, partners, or customers cannot be assessed from this dataset.
Open Questions
- What are the company's reported revenue, operating income, net income, and cash balances across recent periods?
- What is the timing, scope, and outcome of the BiTAC-ADC clinical program referenced in the news?
- Who are the institutional 13F holders, and what are the sizes and direction of their positions?
- What is the terms and the context of the director share purchases relative to the de-SPAC transaction?
- What is the company's cash runway and debt maturity profile underlying the reported Debt/Equity of 0.5?
VRXA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Veraxa Biotech AG (VRXA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 7h ago
Veraxa Biotech stock gains on FDA-aligned testing strategy Yahoo Finance report covering Veraxa Biotech AG (VRXA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 10h ago
VERAXA Biotech AG (VRXA) Reports First In Vivo Proof-of-Concept for BiTAC-ADC TradingView report covering Veraxa Biotech AG (VRXA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 13h ago
A director buys Veraxa Biotech (VRXA) shares at $0.98 and $1. Stock Titan report covering Veraxa Biotech AG (VRXA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 16h ago
VERAXA Biotech (VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing Yahoo Finance report covering Veraxa Biotech AG (VRXA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com Nigeria • 19h ago
Form 4 Veraxa Biotech AG - Post de-SPAC: Marc Gruninger (Director) For: 27 October Investing.com Nigeria report covering Veraxa Biotech AG (VRXA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 22h ago
VERAXA Biotech (VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress Yahoo Finance report covering Veraxa Biotech AG (VRXA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 1d ago
Veraxa Biotech AG Stock Price Prediction: Today, Tomorrow, Next Week (VRXA) Traders Union report covering Veraxa Biotech AG (VRXA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Traders Union • 1d ago
Veraxa Biotech AG Stock Price Today | VRXA Live Chart & News Traders Union report covering Veraxa Biotech AG (VRXA) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
VRXA Bull vs. Bear Conversation Board — What's Your Call at $1.14?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VRXA 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $1.23 (+7.9%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is VRXA (C- • RQD 60/100) a Buy at $1.14?
Welcome to the VRXA (Veraxa Biotech AG) Roar Pit. Current RQD Composite is 60/100 (Roarable Hold — Cautious Neutral) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $0.90 (-21.1%)
Spot @ $1.14 Pump the brakes on VRXA — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on VRXA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Veraxa Biotech AG expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MI MidwestValue Verified K Arena Trader 🐂 BULLISH
🎯 Target: $1.30 (+14.0%)
Spot @ $1.14 VRXA cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on VRXA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.14 (52-wk range $0.95 - $27.36), any beat on forward guidance forces shorts and underweight funds to chase.